NCT01677676View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

September 30, 2012

Conditions
Influenza A
Interventions
BIOLOGICAL

FP-01.1

IM injection

BIOLOGICAL

FP-01.1-Adjuvant

IM injection

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Brisbane

Sponsors
All Listed Sponsors
collaborator

INCResearch Australia Pty Limited

UNKNOWN

lead

Immune Targeting Systems Ltd

INDUSTRY